<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776436</url>
  </required_header>
  <id_info>
    <org_study_id>p15.157</org_study_id>
    <secondary_id>2015-000718-22</secondary_id>
    <nct_id>NCT02776436</nct_id>
  </id_info>
  <brief_title>Reducing Dexamethasone Around Docetaxel Infusion</brief_title>
  <acronym>REDEX</acronym>
  <official_title>Phase 1 Study to Evaluate the Safety of REducing the Prophylactic Dose of DEXamethasone Around Docetaxel Infusion in Patients With Early or Advanced Breast Cancer and Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The manufacturer recommends two different regimens of prophylactic dexamethasone to prevent&#xD;
      hypersensitivity and fluid retention reactions caused by docetaxel: a 3-day regime of&#xD;
      dexamethasone 8mg twice a day starting the day before chemotherapy for breast cancer and for&#xD;
      prostate cancer 3 times 8mg dexamethasone on the day of docetaxel infusion, given the&#xD;
      concurrent use of prednisone 2dd5mg. There is little evidence that supports this high dose&#xD;
      regimen used nowadays. There is need to re-evaluate this high dosage of dexamethasone for&#xD;
      three main reasons. First, dexamethasone can give side effects such as manifestation of&#xD;
      latent diabetes mellitus, immunosuppression, personality changes, irritability, euphoria, or&#xD;
      mania and mood swings. Second, dexamethasone is an immune suppressor, which might inhibit&#xD;
      chemotherapy-induced apoptosis and compromise the efficacy of chemotherapeutic agents. Third,&#xD;
      dexamethasone is a CYP3A4 inducer, which might increase docetaxel clearance. This study aims&#xD;
      to evaluate the feasibility of reducing prophylactic of dexamethasone around docetaxel&#xD;
      infusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Actual">November 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose/recommended dose (RD) of pre-medication dexamethasone around docetaxel infusion, dependent of occurrence of grade III/IV fluid retention and HSR according to the NCI CTCAE v4.03.</measure>
    <time_frame>up to 30 weeks</time_frame>
    <description>If one grade III/IV HSR or fluid retention reaction occurs in one of the six patients within one cohort, then three additional patients will be treated at that dose level. If there are no additional grade III/IV HSR or fluid retention in that additional 3 patients accrual to the next lower dose level will be started. If a grade III/IV HSR or fluid retention occurs in at least 2/6 or 2/9 patients, that dose will not be tolerated as safe and the last previous dose level of dexamethasone will be the RD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose (mmol/L) response due to prophylactic dexamethasone on day 0 before chemotherapy.</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin(mU/L), response due to prophylactic dexamethasone on day 0 before chemotherapy.</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1(nmol/L) response due to prophylactic dexamethasone on day 0 before chemotherapy.</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with toxicity of chemotherapy according to NCI CTCAE v4.03 compared in each dose level of dexamethasone.</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life (descriptive).</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with single nucleotide polymorphisms in the glucocorticoid receptor.</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The effect of dexamethasone on the Maximum concentration of docetaxel (Cmax)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The effect of dexamethasone on Area under the plasma-time concentration curve (AUC) of docetaxel.</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The effect of dexamethasone on Elimination half-lives of docetaxel (T½,α; T½,β; T½,ƴ) of docetaxel.</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The effect of dexamethasone on Total body clearance of docetaxel (Cl) of docetaxel.</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The effect of dexamethasone on Volume of distribution of docetaxel at steady state (Vdss)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of prophylactic dexamethasone will be reduced as follows:&#xD;
STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)&#xD;
STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)&#xD;
STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)&#xD;
STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)&#xD;
STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)&#xD;
STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostate cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of prophylactic dexamethasone will be reduced as follows:&#xD;
STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)&#xD;
STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)&#xD;
STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)&#xD;
STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dose of prophylactic dexamethasone will be reduced for all patients</description>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_label>Prostate cancer</arm_group_label>
    <other_name>dexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>standard prednisone 5 mg bid for patients with prostate cancer</description>
    <arm_group_label>Prostate cancer</arm_group_label>
    <other_name>prednison</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with early breast cancer, or advanced breast cancer or prostate cancer&#xD;
             patients receiving docetaxel (minimal 3 cycles monotherapy or in the regimen 4xAC &gt;&#xD;
             4xdocetaxel or 3xFEC&gt;3xdocetaxel or 6xTAC)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate bone marrow function: white blood cells (WBCs) ≥3.0 x 109/l, neutrophils ≥1.5&#xD;
             x 109/l, platelets ≥100 x 109/l&#xD;
&#xD;
          -  Adequate liver function: bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT&#xD;
             and/or ASAT ≤2.5 x UNL (&lt;5 x UNL in case of liver metastases), Alkaline Phosphatase ≤5&#xD;
             x UNL&#xD;
&#xD;
          -  Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min&#xD;
&#xD;
          -  Survival expectation must be &gt; 3 months&#xD;
&#xD;
          -  Written informed consent according to the local Ethics Committee requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity for docetaxel, paclitaxel or other chemotherapeutic agent or&#xD;
             products containing polysorbate 80 or an earlier experience of anaphylaxis for food,&#xD;
             insect bites, medication or another foreign substance.&#xD;
&#xD;
          -  Existence of edema of the limbs or trunk or elsewhere localized.&#xD;
&#xD;
          -  Active second malignancy&#xD;
&#xD;
          -  Diabetes Mellitus&#xD;
&#xD;
          -  Serious other diseases such as recent myocardial infarction (last 6 months), clinical&#xD;
             signs of cardiac failure or clinically significant arrhythmias&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reinier de Graaf hospital</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga hospital</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden university medical center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.R. Kroep</investigator_full_name>
    <investigator_title>J.R. Kroep, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

